Mikako Fujita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/815955/publications.pdf Version: 2024-02-01



Μικλκό Ειμιτλ

#	Article	IF	CITATIONS
1	In Vitro and In Silico Study of Analogs of Plant Product Plastoquinone to Be Effective in Colorectal Cancer Treatment. Molecules, 2022, 27, 693.	1.7	8
2	A New Series of Indeno[1,2-c]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy. Molecules, 2022, 27, 485.	1.7	3
3	A vitamin D C/D ring-derived compound with cytotoxicity. Medicinal Chemistry Research, 2022, 31, 1120-1125.	1.1	2
4	Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2022, 23, 2400.	1.8	32
5	Discovery of Azaindolin-2-One as a Dual Inhibitor of GSK3β and Tau Aggregation with Potential Neuroprotective Activity. Pharmaceuticals, 2022, 15, 426.	1.7	2
6	Development of chimeric receptor activator of nuclear factorâ€kappa B with glutathione Sâ€ŧransferase in the extracellular domain: Artificial switch in a membrane receptor. Chemical Biology and Drug Design, 2022, 99, 573-584.	1.5	0
7	Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-Î ² Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration. International Journal of Molecular Sciences, 2022, 23, 5047.	1.8	4
8	Promising Antibacterial and Antifungal Agents Based on Thiolated Vitamin K3 Analogs: Synthesis, Bioevaluation, Molecular Docking. Pharmaceuticals, 2022, 15, 586.	1.7	3
9	Natural-product-inspired design and synthesis of thiolated coenzyme Q analogs as promising agents against Gram-positive bacterial strains: insights into structure–activity relationship, activity profile, mode of action, and molecular docking. RSC Advances, 2022, 12, 20507-20518.	1.7	4
10	A New 1,2-Naphthoquinone Derivative with Anti-lung Cancer Activity. Chemical and Pharmaceutical Bulletin, 2022, 70, 477-482.	0.6	3
11	Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Bioorganic Chemistry, 2021, 106, 104510.	2.0	59
12	Fabrication of co-culture device for reproducing cancer metastasis behavior in vitro. The Proceedings of Conference of Kyushu Branch, 2021, 2021.74, C33.	0.0	0
13	Discovery of anti-cell migration activity of an anti-HIV heterocyclic compound by identification of its binding protein hnRNP M. Bioorganic Chemistry, 2021, 107, 104627.	2.0	9
14	Design and synthesis of an anthranyl bridged optically active dinuclear iron(II)-ligand and evaluation of DNA-cleaving activity. Bioorganic and Medicinal Chemistry Letters, 2021, 35, 127782.	1.0	2
15	DNA-cleavage activity of the iron(II) complex with optically active ligands, meta- and para-xylyl-linked N',N'-dipyridylmethyl-cyclohexane-1,2-diamine. Bioorganic and Medicinal Chemistry Letters, 2021, 36, 127834.	1.0	6
16	A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 1099-1109.	0.9	10
17	Crystal Structures of Metallo-β-Lactamase (IMP-1) and Its D120E Mutant in Complexes with Citrate and the Inhibitory Effect of the Benzyl Group in Citrate Monobenzyl Ester. Journal of Medicinal Chemistry, 2021, 64, 10019-10026.	2.9	7
18	Structural insight into host plasma membrane association and assembly of HIV-1 matrix protein. Scientific Reports, 2021, 11, 15819.	1.6	6

Μικακό Γυμτά

#	Article	IF	CITATIONS
19	Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs. Chemico-Biological Interactions, 2021, 345, 109555.	1.7	18
20	Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs. Bioorganic Chemistry, 2021, 114, 105160.	2.0	20
21	Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020. European Journal of Medicinal Chemistry, 2021, 224, 113709.	2.6	16
22	EGFR-Targeted Pentacyclic Triterpene Analogues for Glioma Therapy. International Journal of Molecular Sciences, 2021, 22, 10945.	1.8	15
23	A New Inhibitor of ADAM17 Composed of a Zinc-Binding Dithiol Moiety and a Specificity Pocket-Binding Appendage. Chemical and Pharmaceutical Bulletin, 2021, 69, 1123-1130.	0.6	12
24	A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity. Chemical Biology and Drug Design, 2020, 95, 343-354.	1.5	23
25	In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors. Molecules, 2020, 25, 5190.	1.7	23
26	Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127458.	1.0	13
27	Interruption of Vif/Elongin C interaction: In silico and experimental elucidation of the underlying molecular mechanism of benzimidazole-based APOBEC3G stabilizers. Bioorganic and Medicinal Chemistry, 2020, 28, 115409.	1.4	8
28	Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity. Investigational New Drugs, 2020, 38, 1326-1333.	1.2	19
29	HSP70 induction by bleomycin metal core analogs. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127002.	1.0	1
30	Activation of Ligand Reaction on an Iron Complex: H/D Exchange Reaction of a Low-Spin Bis[2-(Pyridylmethylidene)-1-(2-pyridyl)methylamine]iron(II) Complex. Chemical and Pharmaceutical Bulletin, 2020, 68, 713-716.	0.6	1
31	The stability of HIV-2 Vpx and Vpr proteins is regulated by the presence or absence of zinc-binding sites and poly-proline motifs with distinct roles. Journal of General Virology, 2020, 101, 997-1007.	1.3	Ο
32	Minimum structural requirements for inhibitors of the zinc finger protein TRAF6. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2162-2167.	1.0	19
33	Discovery and structure–activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells. Archiv Der Pharmazie, 2019, 352, e1900170.	2.1	27
34	Anti-cancer activity of the cell membrane-permeable phytic acid prodrug. Bioorganic Chemistry, 2019, 92, 103240.	2.0	18
35	Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. European Journal of Medicinal Chemistry, 2019, 182, 111648.	2.6	70
36	Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement. Molecules, 2019, 24, 3295.	1.7	19

Μικακό Γυμιτά

#	Article	IF	CITATIONS
37	Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents. Bioorganic Chemistry, 2019, 92, 103255.	2.0	31
38	Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity. Molecules, 2019, 24, 3535.	1.7	22
39	New SIRT2 inhibitors: Histidine-based bleomycin spin-off. Bioorganic and Medicinal Chemistry, 2019, 27, 1767-1775.	1.4	18
40	Serial Femtosecond X-Ray Diffraction of HIV-1 Gag MA-IP6 Microcrystals at Ambient Temperature. International Journal of Molecular Sciences, 2019, 20, 1675.	1.8	4
41	Antileukemic Activity of Twig Components of Caucasian Beech in Turkey. Molecules, 2019, 24, 3850.	1.7	14
42	Neuroprotective effects of a novel carnosine-hydrazide derivative on hippocampal CA1 damage after transient cerebral ischemia. European Journal of Medicinal Chemistry, 2019, 163, 207-214.	2.6	10
43	Introduction of H2C2â€type zincâ€binding residues into HIVâ€2 Vpr increases its expression level. FEBS Open Bio, 2018, 8, 146-153.	1.0	3
44	Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Research and Therapy, 2018, 20, 46.	1.6	21
45	The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. Biological and Pharmaceutical Bulletin, 2018, 41, 570-574.	0.6	33
46	Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety. Molecules, 2018, 23, 59.	1.7	48
47	A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3862-3866.	1.0	28
48	A Dithiol Compound Binds to the Zinc Finger Protein TRAF6 and Suppresses Its Ubiquitination. ChemMedChem, 2017, 12, 1935-1941.	1.6	23
49	A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis― Scientific Reports, 2017, 7, 8957.	1.6	50
50	Zinc-binding site of human immunodeficiency virus 2 Vpx prevents instability and dysfunction of the protein. Journal of General Virology, 2017, 98, 275-283.	1.3	14
51	Synthesis, Computational Study, and Evaluation of In Vitro Antimicrobial, Antibiofilm, and Anticancer Activities of New Sulfanyl Aminonaphthoquinone Derivatives. Letters in Drug Design and Discovery, 2017, 14, .	0.4	27
52	Commentary: MARCH8 Inhibits HIV-1 Infection by Reducing Virion Incorporation of Envelope Glycoproteins. Frontiers in Microbiology, 2016, 7, 254.	1.5	3
53	Zinc-mediated binding of a low-molecular-weight stabilizer of the host anti-viral factor apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G. Bioorganic and Medicinal Chemistry, 2016, 24, 4398-4405.	1.4	20
54	Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 43-45.	1.0	7

Μικακό Γυμιτά

#	Article	IF	CITATIONS
55	Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents. Molecules, 2015, 20, 19066-19084.	1.7	74
56	Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine–pyridine–histidine system. Bioorganic and Medicinal Chemistry, 2015, 23, 5476-5482.	1.4	18
57	l-Histidyl-glycyl-glycyl-l-histidine. Amino-acid structuring of the bleomycin-type pentadentate metal-binding environment capable of efficient double-strand cleavage of plasmid DNA. Bioorganic Chemistry, 2015, 62, 8-14.	2.0	7
58	Mutational analysis of HIVâ€2 Vpx shows that proline residue 109 in the polyâ€proline motif regulates degradation of SAMHD1. FEBS Letters, 2015, 589, 1505-1514.	1.3	9
59	Role of poly-proline motif in HIV-2 Vpx expression. Frontiers in Microbiology, 2014, 5, 24.	1.5	2
60	Poly-proline motif in HIV-2 Vpx is critical for its efficient translation. Journal of General Virology, 2014, 95, 179-189.	1.3	13
61	Design and synthesis of lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate derivatives exhibiting high-affinity binding for the HIV-1 MA domain. Organic and Biomolecular Chemistry, 2014, 12, 5006-5022.	1.5	14
62	Commentary on Aptamers for Virus Research. Frontiers in Microbiology, 2012, 3, 52.	1.5	3
63	Structural Biology for Virus Research. Frontiers in Microbiology, 2012, 3, 91.	1.5	4
64	Viral Tropism. Frontiers in Microbiology, 2012, 3, 281.	1.5	30
65	SAMHD1-Dependent and -Independent Functions of HIV-2/SIV Vpx Protein. Frontiers in Microbiology, 2012, 3, 297.	1.5	28
66	The Fourth Major Restriction Factor Against HIV/SIV. Frontiers in Microbiology, 2011, 2, 132.	1.5	2
67	An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G. International Journal of Molecular Medicine, 2011, 28, 613-6.	1.8	23
68	An Artificial Copper Complex Incorporating a Cell-Penetrating Peptide Inhibits Nuclear FactorKAPPA.B (NFKAPPA.B) Activation. Chemical and Pharmaceutical Bulletin, 2011, 59, 1555-1558.	0.6	16
69	HIV-1 Nef impairs multiple T-cell functions in antigen-specific immune response in mice. International Immunology, 2011, 23, 433-441.	1.8	2
70	Role of HIV-1 Nef protein for virus replication in vitro. Microbes and Infection, 2010, 12, 65-70.	1.0	19
71	Multifaceted activity of HIV Vpr/Vpx proteins: the current view of their virological functions. Reviews in Medical Virology, 2010, 20, 68-76.	3.9	33
72	Site-Directed Mutagenesis of HIV-1 vpu Gene Demonstrates Two Clusters of Replication-Defective Mutants with Distinct Ability to Down-Modulate Cell Surface CD4 and Tetherin. Frontiers in Microbiology, 2010, 1, 116.	1.5	7

Μικακό Γυμιτά

#	Article	IF	CITATIONS
73	Highly Sensitive Analysis of the Interaction between HIV-1 Gag and Phosphoinositide Derivatives Based on Surface Plasmon Resonance. Biochemistry, 2010, 49, 5109-5116.	1.2	57
74	Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes and Infection, 2008, 10, 960-967.	1.0	52
75	Functional region mapping of HIV-2 Vpx protein. Microbes and Infection, 2008, 10, 1387-1392.	1.0	13
76	Vpx Is Critical for Reverse Transcription of the Human Immunodeficiency Virus Type 2 Genome in Macrophages. Journal of Virology, 2008, 82, 7752-7756.	1.5	73
77	Generation and characterization of APOBEC3G-positive 293T cells for HIV-1 Vif study. Journal of Medical Investigation, 2007, 54, 154-158.	0.2	9
78	Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity. International Journal of Molecular Medicine, 2006, 18, 679.	1.8	5
79	Comparative study on the structure and cytopathogenic activity of HIV Vpr/Vpx proteins. Microbes and Infection, 2006, 8, 10-15.	1.0	33
80	Construction of gag-chimeric viruses between HIV-1 and SIVmac that are capable of productive multi-cycle infection. Microbes and Infection, 2006, 8, 1075-1081.	1.0	6
81	Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16959-16964.	3.3	111
82	Morphological study on biologically distinct vpx/vpr mutants of HIV-2. Journal of Medical Investigation, 2006, 53, 271-276.	0.2	1
83	Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity. International Journal of Molecular Medicine, 2006, 18, 679-83.	1.8	6
84	Structure–activity relationship of N-methyl-bisindolylmaleimide derivatives as cell death inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3109-3113.	1.0	27
85	Unique characteristics of HIV-1 Vif expression. Microbes and Infection, 2005, 7, 385-390.	1.0	12
86	Establishment of a biological assay system for human retroviral protease activity. Microbes and Infection, 2005, 7, 820-824.	1.0	7
87	Determination of HIV-1 infectivity by lymphocytic cell lines with integrated luciferase gene. International Journal of Molecular Medicine, 2004, 14, 1073.	1.8	1
88	High Level Expression of Human Immunodeficiency Virus Type-1 Vif Inhibits Viral Infectivity by Modulating Proteolytic Processing of the Gag Precursor at the p2/Nucleocapsid Processing Site. Journal of Biological Chemistry, 2004, 279, 12355-12362.	1.6	56
89	Functional analysis of HIV-1 genes derived from Japanese long-term nonprogressors and progressors for AIDS. Microbes and Infection, 2004, 6, 799-805.	1.0	12
90	Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes and Infection, 2004, 6, 791-798.	1.0	69

Μικακό Γυμτά

#	Article	IF	CITATIONS
91	Determination of HIV-1 infectivity by lymphocytic cell lines with integrated luciferase gene. International Journal of Molecular Medicine, 2004, 14, 1073-6.	1.8	6
92	Vpx and Vpr proteins of HIV-2 up-regulate the viral infectivity by a distinct mechanism in lymphocytic cells. Microbes and Infection, 2003, 5, 387-395.	1.0	43
93	Amino Acid Residues 88 and 89 in the Central Hydrophilic Region of Human Immunodeficiency Virus Type 1 Vif Are Critical for Viral Infectivity by Enhancing the Steady-State Expression of Vif. Journal of Virology, 2003, 77, 1626-1632.	1.5	31
94	Susceptibility of HVS-immortalized lymphocytic HSC-F cells to various strains and mutants of HIV/SIV. International Journal of Molecular Medicine, 2003, 11, 641.	1.8	10
95	Susceptibility of HVS-immortalized lymphocytic HSC-F cells to various strains and mutants of HIV/SIV. International Journal of Molecular Medicine, 2003, 11, 641-4.	1.8	13
96	Apparent lack of trans-dominant negative effects of various vif mutants on the replication of HIV-1. Microbes and Infection, 2002, 4, 1203-1207.	1.0	6
97	Subtle mutations in the cysteine region of HIV-1 Vif drastically alter the viral replication phenotype. Microbes and Infection, 2002, 4, 621-624.	1.0	12
98	Analysis of the cell-dependent replication potentials of human immunodeficiency virus type 1 vif mutants. Microbes and Infection, 2001, 3, 1093-1099.	1.0	7
99	Cyclophilin A-Independent Replication of a Human Immunodeficiency Virus Type 1 Isolate Carrying a Small Portion of the Simian Immunodeficiency Virus SIV MAC gag Capsid Region. Journal of Virology, 2001, 75, 10527-10531.	1.5	14
100	Growth characteristics of SHIV without the vpu gene. International Journal of Molecular Medicine, 2001, 8, 641-4.	1.8	5
101	Regulation of cell cycle and apoptosis by human immunodeficiency virus type 1 Vpr. Microbes and Infection, 2000, 2, 1011-1017.	1.0	27
102	Physiological significance of apoptosis in animal virus infection. Microbes and Infection, 2000, 2, 1111-1117.	1.0	130
103	Cell-dependent gag mutants of HIV-1 are crucially defective at the stage of uncoating/reverse transcription in non-permissive cells. Microbes and Infection, 2000, 2, 1419-1423.	1.0	8
104	Elimination of HIV-1 plasmid DNA from virus samples obtained from transfection by calcium–phosphate co-precipitation. Journal of Virological Methods, 2000, 90, 99-102.	1.0	14
105	Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5). Gene, 1998, 207, 135-140.	1.0	19
106	Synthetic inhibitors of regulatory proteins involved in the signaling pathway of the replication of human immunodeficiency virus 1. Bioorganic and Medicinal Chemistry, 1997, 5, 205-215.	1.4	16
107	Man-made Inhibitors of Transcription Factors Involved in the Replication of Human Immunodeficiency Virus Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 1997, 55, 697-704.	0.0	2
108	Metal-Chelating Inhibitors of a Zinc Finger Protein HIV-EP1. Remarkable Potentiation of Inhibitory Activity by Introduction of SH Groups. Journal of Medicinal Chemistry, 1996, 39, 503-507.	2.9	34

Μικακό Γυμτά

#	Article	IF	CITATIONS
109	Novel Zinc Chelators with Dual Activity in the Inhibition of the .kappa.B Site-Binding Proteins, HIV-EP1 and NFkappa.B. Journal of Medicinal Chemistry, 1995, 38, 3264-3270.	2.9	37
110	Novel Zinc Chelators Which Inhibit the Binding of HIV-EP1 (HIV Enhancer Binding Protein) to NFkappa.B Recognition Sequence. Journal of Medicinal Chemistry, 1994, 37, 4267-4269.	2.9	24
111	Synthesis and biological properties of 3-[()-2-(1,2,3-Thiadiazolyl)ethenyl]-substituted cephalosporins and related compounds: new oral cephalosporins. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2225-2230.	1.0	3
112	A Facile Synthesis of 4-Formyl-1,2,3-thiadiazole. Synlett, 1992, 1992, 95-96.	1.0	13
113	Thermal high yield aromatic arylation with α-azohydroperoxide (part 1). A novel free radical aromatic arylation reaction. Tetrahedron Letters, 1989, 30, 963-966.	0.7	8
114	Stereochemistry of the addition of diarylsilylenes to cis- and trans-2-butenes. Journal of the American Chemical Society, 1988, 110, 3310-3311.	6.6	64